¡Ya estamos en !
Descubre más
Humacyte Inc Warrant
HUMAW
HUMAW
Dejó de cotizar
HUMAW dejó de cotizar en bolsa el 25 de agosto de 2026.
Acerca de: Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Empleados: 184
Noticias
Positivo
Neutral
Negativo
Sentimiento
3 meses
Positivo
0%
Neutral
0%
Negativo
0%
Gráficos de precios implementados con Lightweight Charts™